Compare ATHM & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | ANIP |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2013 | 1999 |
| Metric | ATHM | ANIP |
|---|---|---|
| Price | $17.78 | $81.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $28.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 710.2K | 268.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.83% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | N/A | $21.01 |
| Revenue Next Year | $4.77 | $17.59 |
| P/E Ratio | ★ $12.13 | $63.79 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $15.57 | $62.14 |
| 52 Week High | $29.92 | $99.50 |
| Indicator | ATHM | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 54.87 |
| Support Level | $16.22 | $76.73 |
| Resistance Level | $18.81 | $83.61 |
| Average True Range (ATR) | 0.83 | 2.34 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 72.84 | 77.12 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.